유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - ХИВ инфекции - Антивирусни средства за системно приложение - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

paion deutschland gmbh - remimazolam besilate - Съзнателно седация - психолептици - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - Полови хормони и слиза на половата система, - oral contraceptive.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - Полови хормони и слиза на половата система, - Устна контрацепция. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - псориазис - Имуносупресори - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - Лупус еритематозус, системен - Имуносупресори - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - псориазис - Имуносупресори - treatment of moderate-to-severe plaque psoriasis in adults.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - Дерматит, Атопич - Други дерматологични препарати - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

hra pharma rare diseases - Кетоконазол - Синдром на cushing - Антимикотици за системна употреба - ketoconazole hra е показан за лечение на ендогенен синдром на cushing при възрастни и юноши на възраст над 12 години.

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

amgen europe b.v. - денозумаб - bone resorption; osteoporosis, postmenopausal - Лекарства за лечение на костни заболявания - Лечение на остеопороза при жени в постменопауза и при мъже с повишен риск от фрактури. При жени в постменопауза prolia значително намалява риска от вертебрални, без вертебрални и Хип фрактури. Лечение на загуба на костна маса, свързана с хормоналната абляции при мъже с рак на простатата повишен риск от фрактури. При мъжете с рак на простатата, получаващи хормонална аблация, prolia значително намалява риска от вертебрални фрактури.